Evaluation of lytic activity of staphylococcal bacteriophage Sb‐1 against freshly isolated clinical pathogens |
| |
Authors: | Leila Kvachadze Nana Balarjishvili Tamila Meskhi Ekaterine Tevdoradze Natia Skhirtladze Tamila Pataridze Revaz Adamia Temur Topuria Elizabeth Kutter Christine Rohde Mzia Kutateladze |
| |
Affiliation: | 1.Laboratory of Genetic Engineering and Biotechnology, G. Eliava Institute of Bacteriophages, Microbiology and Virology, 3, Gotua str., Tbilisi 0160, Georgia;2.Cystic Fibrosis National Center, 2/6 Lubliana str., Tbilisi 0160, Georgia;3.DZMZ Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Inhoffenstraße 7 B,38124 Braunschweig, Germany;4.Evergreens State College, 2700 Parkway, NW, Olympia, WA 98505, USA. |
| |
Abstract: | In recent decades the increase in antibiotic‐resistant bacterial strains has become a serious threat to the treatment of infectious diseases. Drug resistance of Staphylococcus aureus has become a major problem in hospitals of many countries, including developed ones. Today the interest in alternative remedies to antibiotics, including bacteriophage treatment, is gaining new ground. Here, we describe the staphylococcal bacteriophage Sb‐1 – a key component of therapeutic phage preparation that was successfully used against staphylococcal infections during many years in the Former Soviet Union. This phage still reveals a high spectrum of lytic activity in vitro against freshly isolated, genetically different clinical samples (including methicillin‐resistant S. aureus) obtained from the local hospitals, as well as the clinics from different geographical areas. The sequence analyses of phage genome showed absence of bacterial virulence genes. A case report describes a promising clinical response after phage application in patient with cystic fibrosis and indicates the efficacy of usage of Sb‐1 phage against various staphylococcal infections. |
| |
Keywords: | |
|
|